Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.

Abstract: Disclosed are methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer, and methods of cancer treatment and modified T cells with anti-tumor T cell receptors (TCRs).

Abstract: Chimeric antigen receptors (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALY(SEQ ID NO: 94)/HLA-A2 are disclosed. The CAR can be used to treat PRAME/HLA-A2 expressing cancers such as the t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia (AML).

Abstract: The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through cytokine signaling or cytokine receptor signaling.

Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.

Abstract: The present disclosure provides a chimeric antigen receptor (CAR) specific for albumin. The present disclosure also provides compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising a polynucleotide encoding the CAR, engineered cells comprising the CAR, and method using the same.

Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.

Abstract: The present disclosure relates to opioid sparing compositions and use of the same for reducing opioid use. Such compositions and methods method may be used for reducing pain or reducing opioid use or increasing mobility in subjects using an opioid.

Abstract: The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPAR?/? agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPAR?/? agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPAR?/? agonist to the subject.

Abstract: The present application provides methods and processes for pharmaceutical formulations comprising mesenchymal stem cell secretome for use in ocular treatments, as well as methods for manufacturing and packaging such formulations.

Abstract: The invention discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering from bipolar disorder.

Abstract: The present invention generally relates to modulating insulin expression and production by targeting CD47. In a particular aspect, the invention relates increasing insulin expression by silencing or blocking CD47. In another aspect, the present invention relates to the delivery of insulin to a subject by pancreatic beta islet cells. Specifically, the present invention relates to the production of modified pancreatic beta islet cells that have increased insulin expression and production resulting from silencing or blocking CD47, which are suitable for beta cell transplantation, and methods of their production.

Abstract: The present disclosure relates to the engraftment and proliferation of cells in fat-associated lymphoid clusters (“FALCs” or “milky spots”), which may be used to generate functional ectopic tissue. The present disclosure further provides methods and compositions for grafting and proliferating cells, in FALCs by activating the lymphotoxin beta receptor (LT?R) and/or NF-?B-inducing kinase (NIK) signaling pathway. The present disclosure also provides for methods and compositions to establish ectopic liver tissue in FALCs (milky spots) and to use such ectopic liver tissue for therapeutic benefit, and provides methods and compositions to generate ectopic kidney tissue in FALCs, which can be used in a subject for therapeutic benefit.

Abstract: Disclosed are engineered multicellular organisms. Also disclosed are systems and methods for designing, preparing, and utilizing the engineered multicellular organisms including methods of modulating tissue formulation and healing.

Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.

Abstract: The invention provides, for the first time, cells that comprise enhanced CD16, CD32, or CD64 expression to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO?), that further comprise the enhanced CD16, CD32, or CD64 expression. The invention encompasses cells derived from the pluripotent cells.

Abstract: A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.

Abstract: Immunogenic compositions comprising (a) a bacterial population comprising at least three pathogenic bacterial species selected from the group consisting of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, and Moraxella catarrhalis, wherein the bacteria are inactivated bacteria comprising the whole bacterial cell wall, and (b) one or more tumor antigenic determinants. Pharmaceutical compositions comprising the immunogenic compositions and methods for preventing and/or treating tumors in subjects in need thereof.

Abstract: Therapeutic modalities are provided involving the use of specific repertoirs of PRR ligands to ameliorate immune dysregulation in a perioperative period. In effect, innate immune system signaling is provoked in the perioperative period so as to facilitate a targeted immune response following surgery. Subjects may accordingly be treated with immunogenic formulations tailored to a specific target tissue to treat a subject during the perioperative period surrounding surgery to remove a solid tumor, where the target tissue is the site of the tumor or a characteristic site of metastasis for the cancer.

Abstract: Provided herein are pharmaceutical compositions comprising a bacterial population and one or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be encompassed by containers or packaging forms. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and/or metabolic diseases. Also provided herein are methods for manufacturing the pharmaceutical composition.

Abstract: A method to prevent, inhibit or treat an inflammatory disease in a mammal, is provided that includes administering to a mammal in need thereof an effective amount of one or more isolated gut microbes and one or more phytoestrogens.

Abstract: This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

Abstract: The present invention relates to a composition comprising a Leuconostoc citreum strain or a culture thereof as an active ingredient for preventing, improving or treating intestinal damage, specifically intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis or chemotherapy. According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various intestinal damages such as inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy, the composition can be usefully used as a composition for the treatment, prevention or improvement of human or animal intestinal damage.

Abstract: A probiotic microcapsule for the treatment of reproductive tract infection and a preparation method and application thereof are provided. The probiotic microcapsule is obtained by coating probiotics with the coating material. The probiotics include one or several of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus crimpus, Lactobacillus brevis, Lactobacillus salivary, Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacillus bulgaricus. As probiotics screened in reproductive tract, it has high safety; It endows probiotics with adhesion function to ensure their effect in the reproductive tract; It overcomes the defects of current antibiotic therapy; It is expected to be used in a variety of reproductive tract infectious diseases.

Abstract: The present disclosure provides the use of Lactobacillus paracasei ET-22 in enhancing resistance of the intestinal tract to bacterial infection and improving intestinal immunity. Particularly, the present disclosure provides the use of a Lactobacillus paracasei in the preparation of a composition for improving intestinal immunity, wherein the Lactobacillus paracasei has a deposit number of CGMCC 15077. The present inventors have discovered that this bacteria strain alone can significantly improve the resistance of the intestinal tract to bacterial infection, combat invasion by pathogenic bacteria in the intestinal system, maintain the intestinal barrier function, and/or prevent diarrhea caused by pathogenic bacteria.

Abstract: The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.

Abstract: A pharmaceutical composition for treatment of a tumor expressing at least one of a plurality of receptor proteins including CD24, Axl, DC-SIGN, Tyro3, MER, MerTK TIM-1, TIM-4, TLR3, TLR8, RIG-1, and MDA5. The pharmaceutical composition includes either a purified viral RNA of an oncolytic Zika virus in a liposome and a pharmaceutically acceptable carrier, or a pharmaceutically acceptable carrier and a unit dosage form of an oncolytic Zika virus.

Abstract: An antibiotic with Spirulina platensis and plant extracts is an antibiotic composition including a combination of Spirulina platensis, an essential oil of Magnolia officinalis, and an essential oil of mumie. In an embodiment, the antibiotic composition may be effective in treating Acinetobacter baumannii infections. In a further embodiment, the antibiotic composition may be effective in treating multidrug resistant (MDR) and/or extremely drug resistant (XDR) Acinetobacter baumannii infections. In an embodiment, the antibiotic composition may be administered to a subject in need thereof to treat or prevent an Acinetobacter baumannii infection, such as a MDR or XDR Acinetobacter baumannii infection.

Abstract: An antibiotic with Spirulina platensis and plant extracts is an antibiotic composition including a combination of Spirulina platensis, an essential oil of Magnolia officinalis, and an essential oil of mumie. In an embodiment, the antibiotic composition may be effective in treating Acinetobacter baumannii infections. In a further embodiment, the antibiotic composition may be effective in treating multidrug resistant (MDR) and/or extremely drug resistant (XDR) Acinetobacter baumannii infections. In an embodiment, the antibiotic composition may be administered to a subject in need thereof to treat or prevent an Acinetobacter baumannii infection, such as a MDR or XDR Acinetobacter baumannii infection.

Abstract: An antibiotic with Spirulina platensis and plant extracts is an antibiotic composition including a combination of Spirulina platensis, an essential oil of Magnolia officinalis, and an essential oil of mumie. In an embodiment, the antibiotic composition may be effective in treating Acinetobacter baumannii infections. In a further embodiment, the antibiotic composition may be effective in treating multidrug resistant (MDR) and/or extremely drug resistant (XDR) Acinetobacter baumannii infections. In an embodiment, the antibiotic composition may be administered to a subject in need thereof to treat or prevent an Acinetobacter baumannii infection, such as a MDR or XDR Acinetobacter baumannii infection.

Abstract: A lichen extract-based formulation containing a mixture of reindeer lichen extract (Cladonia rangiferina), lung lichen extract (Lobaria pulmonaria), and witch's hair lichen extract (Alectoria sarmentosa); feed pellet, protein block and solution containing the lichen extract-based formulation; lichen extract-based spray cleaner formulation and methods for administration of the formulations to cervids are disclosed.

Abstract: A pharmaceutical composition that is effective in relieving pain from joint and muscle strain is disclosed herein. The pharmaceutical composition comprises a combination of Pecan kernels; Eucommia ulmoides barks; and Psoralea corylifolia seeds as it active ingredients.

Abstract: The present disclosure encompasses compositions prepared from kiwifruit. In particular, the invention encompasses compositions prepared from gold varieties of Actinidia chinensis. Also encompassed are methods of preparing these compositions. Further encompassed are methods of using these compositions, in particular, for treating or preventing disorders of the gastrointestinal system, including amongst others: inflammation, constipation, bowel irregularity, microbiota imbalances, irritable bowel syndrome, and inflammatory bowel disease.

Abstract: Compositions and methods are provided for the treatment of a variety of human cancers. The compositions generally comprise at least one cannabinoid, or an extract of Cannabis spp. combined with at least one other cannabinoid, terpene, and/or at least one flavonoid. Methods for optimizing compositions using artificial intelligence algorithms are also provided.

Abstract: Proposed is an immunity-enhancing composition containing a Syneilesis palmata extract as an active ingredient. The Syneilesis palmata extract activates macrophage phagocytosis, promotes the production of nitric oxide (NO), inducible nitric oxide synthase (iNOS), interleukin-1? (IL-1?), and tumor necrosis factor-? (TNF-?), and induces TLR2/4 stimulation. In addition, the Syneilesis palmata extract exhibits immunity-enhancing activity by activating macrophage autophagy, suggesting that the Syneilesis palmata extract can be applied to a variety of health supplement foods.

Abstract: The invention relates to an extract of top growth of holy basil, in particular of Ocimum sanctum, a method for preparing the extract, and the extract obtainable by said method. The invention also relates to a composition comprising such an extract, the composition advantageously being a cosmetic, pharmaceutical or dermatological composition. The invention also relates to such a composition or such an extract for use in preventing or treating disorders or diseases of the skin, the mucous membranes or the skin appendages, and for use in preventing or treating vascular disorders. Finallyc the invention relates to a cosmetic care method for the skin, skin appendages or mucous membranes, with a view to improving the condition or appearance thereof, which method consists in administering such a composition or such an extract.

Abstract: The invention provides a composition comprising an extract of black pepper seeds having ?-caryophyllene as a bioactive ingredient. The invention also provides a method of providing pain relief, comprising administering to a subject in need thereof an effective amount of the inventive composition.

Abstract: Disclosed is to provide a composition for skin-whitening or preventing or improving skin wrinkles, comprising a green tea extract which has modified amounts of ingredients. More specifically, the extract and composition according to one aspect of the present disclosure are derived from natural plants that cause less irritation to the skin and are eco-friendly, thus they are safe, and thereby the extract and composition can exhibit excellent effects of effectively inhibiting melanin production and tyrosinase activity and preventing or improving skin whitening, and can exhibit excellent effects of effectively inhibiting the expression of MMP-1 and preventing or improving skin wrinkles.

Abstract: Improved compositions of reversible monoamine oxidase inhibitors are obtained by improved methods of alcohol removal from distillates of fermented agave extracts.

Abstract: The present invention provides a process for preparing a pharmaceutical preparation which is to be used for treatment of the viral infections, specifically the infections caused by related RNA virus such as Coronavirus (COVID-19) disease. The present invention also provides the method of treating viral infections or the infections caused by related RNA viruses such as COVID-19 disease using Hordeum or Barley or Barley extracts or the pharmaceutical preparation comprising them and the combinations thereof. The present process is simple, economical, bio friendly, and industrially applicable.

Abstract: The present invention provides compositions formulated for topical administration to a penis of a person to enhance sexual responsiveness in the person, to enhance sexual performance, erection and stamina, and to increase the physical size of the penis, where the compositions comprise active components from herbal or plant origin including maca, tongkat ali, cordyceps, ginseng, fructus schisandrae. morinda root, rhodiola, rosea cordyceps sinensis, ginger, jasmine, sandalwood, leeks, camellia seed, jojoba oil and cannabidiol. The preferred composition is in the form of a massage oil, to be applied topically to the skin of the penis.

Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more free/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: Disclosed are compounds having structural formulas (I)-(XI), and related pharmaceutical compositions. Also disclosed are methods of selecting and treating human subjects suffering from a kidney disease, using the compounds of formulas (I)-(XI), and methods of determining the efficacy of TRPC5 inhibitor therapies using the same.

Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.

Abstract: The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.

Abstract: The present invention relates to a peptide, or derivative thereof, having length equal to or lower than (30) amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, for use as a medicament, preferably for use in the treatment of conditions associated to/caused by deficient angiogenesis or conditions beneficing from increased angiogenesis.

Abstract: The present disclosure provides a composition comprising Amuc_1100 (or a genetically engineered host cell expressing the Amuc_1100) and an immune checkpoint modulator, and uses thereof.